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Hormesis: A New Religion? 
Cook and Calabrese (2006) make inaccu-
rate claims about our perspective on horme-
sis (Thayer et al. 2005). They define
hormesis as “low-dose stimulation and
high-dose inhibition,” declaring “beneficial/
harmful effects should not be part of the
definition, but reserved to subsequent
evaluation. . . .” Yet, they advocate higher
permissible environmental levels of haz-
ardous agents based on purported health
benefits. Cook and Calabrese promote
changing the way carcinogens are regulated
to accommodate hormesis, recognizing that
this “would result in cancer risk assessment
values about 100- to 200-fold higher than
currently employed” (Calabrese and Cook
2005). Previously, Calabrese and Baldwin
(2003a) stated, “agencies will need to accept
the possibility (actually, the likelihood) that
toxic substances, even the most highly toxic
(e.g., cadmium, lead, mercury, dioxin,
PCBs, etc.) can cause beneficial effects at
low doses.” 
We are concerned that changing health
policies to permit higher exposures based
on alleged benefits would be harmful, par-
ticularly to susceptible subgroups and indi-
viduals exposed to mixtures (Thayer et al.
2005). Instead Cook and Calabrese (2006)
suggest that policy decision making “may
tend to bring various subgroups in the
population together to debate one group’s
health benefit against another group’s
health risk.” To pit one group against
another is absurd. Health-protective default
assumptions that are used to compensate
for uncertainties should not be dismissed
based on untested propositions that likely
incur greater risks.
Contrary to statements made by Cook
and Calabrese (2006), in our article (Thayer
et al. 2005) we never claimed that hormetic
responses are rare. Rather, we argued that
hormesis should not be assumed as universal.
In fact, we have published on nonmonotonic
dose responses in biological systems (Kohn
and Melnick 2002; Welshons et al. 2003).
We argue against the assumption that “an
exposure limit in the range of the maximum
stimulation could promote appreciable
benefits in public health” for the general
population (Cook and Calabrese 2006).
Yet, we fully support addressing non-
monotonic dose–response relationships in
risk assessments.
Further, we never claimed that “compre-
hensive mechanistic knowledge is necessary”
before making a public health decision. In
fact, we have a history of arguing the con-
trary. Indeed, if this standard were operating
today, we might still be debating the dangers
of tobacco smoke and benzene, among many
others. Calabrese appears to overstate the
frequency of hormetic dose–response curves.
Some responses considered “stimulatory” are
not, such as decreased interleukin-2 release,
blood pressure, memory, and prolactin level
(Calabrese and Baldwin 2003b). His horme-
sis database contains U- or J-shaped curves
where the low dose “stimulation” is actually
decreased compared to control values
(Calabrese and Baldwin 2001). There
should be some mechanistic indication of
what specifically is being stimulated (and
inhibited at higher doses) before consider-
ing a curve hormetic. Otherwise, the
empirical observations of Calabrese and col-
leagues simply reflect nonmonotonic dose
responses.
The quote we used from the BEIR VII
(National Research Council 2005) that
draws attention to the lack of evidence of a
health benefit from low doses of ionizing
radiation was not misleading; Kaiser (2005)
also reported that the National Research
Council dismissed “the hypothesis that tiny
amounts of [ionizing] radiation are harmless
or even beneficial,” noting that cancer risk
increases proportionally with exposure. In
contrast, Calabrese and Cook (2005)
claimed that all or most carcinogens have a
hormetic dose(s) at which tumors will be
decreased. This is contrary to what we know
about the carcinogenicity of chemicals and
radiation. 
Labeling a dose response as hormetic to
justify higher exposures and claimed bene-
fits for the general population without pro-
viding scientific evidence is counter to
public-health protective assumptions. For
example, cadmium has been touted as a
hormetic agent with benefits (Calabrese and
Baldwin 2003) because low doses are associ-
ated with decreases in testicular tumors in
rats. However, Waalkes et al. (1997, 1988)
reported increases in prostate tumors within
the hormetic dose range for testicular
tumors. In our article (Thayer et al. 2005),
we emphasized the latter, whereas it was
seemingly ignored by Calabrese and
Baldwin (2003), because cadmium is a
human carcinogen and includes associations
with cancer of the prostate and other organs
[National Toxicology Program (NTP)
2004]. In addition, differential susceptibility
must be addressed because it is well estab-
lished that cancer and other health risks from
ionizing radiation, some chemotherapeutics,
and passive tobacco smoke are much greater
for those exposed in utero or as children.
We should not allow another tragedy such
as the one caused by diethylstilbestrol.
Disease prevention strategies should not
rely on higher environmental exposures to
known toxicants (e.g., cadmium, lead, mer-
cury, dioxin, polychlorinated biphenyls).
Setting environmental exposure limits based
on ranges of maximum stimulation (i.e.,
equated with postulated hormetic benefits)
is a totally unjustified public health policy
that would impose greater involuntary risks
on sizable segments of the population. 
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Suggested Corrections to the
Farm Family Exposure Study
Acquavella et al. (2004) reported glyphosate
exposure analyses from the Farm Family
Exposure Study (FFES) using biomonitoring.
The authors “analyzed urine samples for
creatinine to assess the completeness of
daily samples,” but inadvertently used as
“the normal range” 0.8–1.4 mg/dL and
0.5–1.1 mg/dL for males and females,
respectively, which are the normal ranges of
serum creatinine [National Institutes of
Health (NIH) 2003]. The NIH normal val-
ues for urine creatinine are 24-hr total
excretion values ranging from “500 mg/day
to 2000 mg/day” (NIH 2006). Thus,
Acquavella et al. (2004) needed to compare
the 24-hr creatinine collection (urine creati-
nine concentration × urine volume) to each
individual’s normative value of daily creati-
nine excretion based on age, sex, and body
surface area (Cockcroft and Gault 1976).
Acquavella et al. (2004) also did not cor-
rect for the initial conditions. Of 47 farmers,
7 had 24-hr urinary glyphosate concentra-
tions above the minimum detectable value
of 1 ppb immediately before the start of
their application. Such a farmer who had
zero exposure during the monitored appli-
cation would have excreted glyphosate over
the following 4-day collection period in an
amount estimable from the measured indi-
vidual excretion rates. For a truly unex-
posed applicator to be shown to have a
dosage statistically similar to zero, this esti-
mated total 4-day excretion with zero expo-
sure must be subtracted from the 4-day
collection value.
In addition, Acquavella et al. (2004)
evaluated one application per family and
called it only a “potential limitation,” with-
out realizing that this may vitiate their
study. If all 47 FFES subjects with complete
data had an identical exposure distribution,
any single applicator sampled 47 different
times would have an expectation of present-
ing exposure data with a statistically similar
mean and variance as the FFES 47 sampled
only once each. Therefore Acquavella et al.
(2004) cannot reject the possibility that all
47 applicators have a similar exposure
distribution by taking only one sample from
each. This is because an applicator’s pesticide
exposure is a stochastic process (accidents
happen) that varies wildly from day to day,
unlike the applicator’s weight that is a rela-
tively constant process that barely varies
from day to day. Therefore a single meas-
ured exposure provides no statistical infor-
mation for estimating the applicator’s mean
exposure over any time period other than
the day measured. Furthermore, farmers’
pesticide exposures are not results of a sta-
tionary process, (defined as a time series in
which the mean and variance of measured
exposures, over a sufficiently long period
from time 1 to time 2, are constants inde-
pendent of choice for time 1). In an earlier
study, we (Mage et al. 2000) successfully
modeled the risk of accidental high pesti-
cide exposure events in the Agricultural
Health Study population as decreasing with
the increasing lifetime number of applica-
tion days. As one might expect, we showed
that as an applicator gains experience, the
risk of high exposure decreases. Therefore
differences in lifetime experience of the
FFES applicators prior to sampling intro-
duce another variance component into the
analysis.
In conclusion, Acquavella et al. (2004)
treated a single sample at the end of a non-
stationary time series—with declining
mean and finite variance—as if it were
actually the true mean value of a stationary
process with zero variance. I recommend
that Acquavella et al. (2004) consider revis-
ing their analyses by correcting properly for
incomplete urine collection, correcting for
the initial condition of prior glyphosate
exposure, and adjusting for the experience
of the applicator (lifetime number of appli-
cation days) as an explanatory variable.
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The Farm Family Exposure
Study: Acquavella et al.
Respond
We thank Mage for his comments. In our
article on glyphosate in the Farm Family
Exposure Study (FFES) (Acquavella et al.
2004), we used 24-hr urinary creatinine to
assess the completeness of daily samples over
5 days for the 48 participating farmers. We
erred by summarizing the results as micro-
grams per deciliter instead of micrograms per
day. Using an expected daily excretion of
566 µg/day as the lower end of the normal
range (Bingham et al. 1988; Forman 2003),
only four 24-hr urine samples over 5 days
were below that lower limit. Therefore, the
completeness of urine collection for the
applicators was exceptional. Further details
of the urine collection and our assessment of
completeness can be found in a related article
(Baker et al. 2005).
Mage criticizes us for not subtracting
preapplication urine values in our assess-
ment of systemic dose related to on-study
applications. Indeed, seven of the applica-
tors had detectable glyphosate in their urine
on the day before their on-study application
(Acquavella et al. 2004). Values were 1.1,
2.6, 3.9, 5.3, 8.3, 9.8, and 15.4 ppb. We
intentionally did not correct for these initial
values for two reasons. First, from an epi-
demiologic and public health standpoint, it
is instructive to know the total dose for
farmers during and after an application,
which, for example, could then be com-
pared to levels of toxicologic significance.
Second, the overestimate caused by this
practice is trivial for glyphosate in both an
absolute and relative sense. Consider that
glyphosate has a U.S. Environmental
Protection Agency (EPA) reference dose of
2 mg/kg/day (U.S. EPA 1999), and the
highest systemic dose we estimated in our
study was 0.004 mg/kg/day. The requested
corrections would be to the ten thousandths
of a milligram per kilogram per day or less.
Last, Mage calls the fact that we only
evaluated one application per farm family a
limitation that may vitiate our study. That is
a strong indictment for a study that compre-
hensively assessed exposure for farm families
related to a single application of three pesti-
cides to an extent not seen before. We agree
that characterizing intraperson variation in
absorbed pesticide dose over several seasons
would provide valuable information, but
that was not the objective of the FFES.
Nevertheless, Mage’s claim that we cannot
reject the possibility that all 47 applicators
have the same exposure distribution is
refuted by our observations that absorbed
dose was related to specific practices (e.g.,
not wearing gloves) and by similar findings
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Risk Assessment and
Epidemiologic Evidence in
Environmental Health Science
There appears to be a serious conceptual error
about the role of the various environmental
health sciences in Kundi’s otherwise interesting
and informative commentary on “Causality
and the Interpretation of Epidemiologic
Evidence” (Kundi 2006). This error is exempli-
fied in his next-to-last paragraph: 
Most risk assessment procedures demand that for
chronic diseases such as cancer there must be epi-
demiologic evidence before an extrinsic agent can
be ascribed a hazardous potential for human health.
In fact, it is solely toxicologic evidence that is
used for the overwhelming majority of
agents to which a “hazardous potential for
human health” is ascribed. I am unaware of
any risk assessment process that requires epi-
demiology to recognize hazardous potential
for human health. 
Perhaps Kundi (2006) meant that there
must be epidemiologic evidence for a chemi-
cal to achieve the level of a known or proven
cause of a hazard to human health. However,
the misunderstanding in the above quote per-
meates his commentary. 
As Kundi (2006) correctly recognized, it
is better to prevent the introduction or use
of agents that would cause adverse effects
eventually identifiable in an epidemiologic
study. Such prevention is primarily the role
of predictive toxicology. Yet, as Kundi
stated in his abstract, his recommended dia-
logue approach to “the potential for disease
causation” starts with epidemiology. 
Kundi (2006) concluded that the princi-
ple that every disease has a cause is metaphysi-
cal, but still has heuristic value. He appears to
mean that the principle of causation helps us
explore the potential that environmental fac-
tors cause human disease—and that we do so
by developing models, such as risk assessment,
that approximate reality without achieving
certainty. However, a risk assessment, or any
other model, that must depend on epidemio-
logic evidence to recognize the potential for
disease causation represents a failure of envi-
ronmental health science. 
The author declares he has no competing finan-
cial interests.
Bernard D. Goldstein
Graduate School of Public Health 
University of Pittsburgh
Pittsburgh, Pennsylvania
E-mail: bdgold@pitt.edu
REFERENCE
Kundi M. Causality and the interpretation of epidemiologic evi-
dence. 2006. Environ Health Perspect 114:969–974. 
Risk Assessment and
Epidemiologic Evidence: 
Kundi Responds
I appreciate Goldstein’s remarks about the
role of epidemiology in risk assessment of
environmental hazards and the opportunity
to clarify my standpoint. 
With reference to the International
Agency for Research on Cancer’s classifica-
tion scheme of agents for their carcinogenic-
ity in humans and other schemes such as
that of the U.S. Environmental Protection
Agency (EPA), Pitot and Dragan (2001)
stated in Casarett and Doull’s Toxicology: 
In spite of the limitations of these classifications,
an agent cannot be proven to be carcinogenic for
the human unless substantial epidemiologic evi-
dence supporting such a claim is available.
Although this statement refers to carci-
noma and not to the broader class of chronic
diseases, it seems to be very close to my
statement (Kundi 2006) that Goldstein criti-
cizes. However, Goldstein particularly
emphasizes that I may have meant that
“there must be epidemiologic evidence for a
chemical to achieve the level of a known or
proven cause of a hazard to human health.”
The reader may have noticed that I never
used the term “proven” (Kundi 2006), and I
deliberately did not. In my opinion we cannot
reach the level of a proven cause. Our knowl-
edge is always incomplete; although we may
be quite sure about a factor causing a disease,
it may turn out to be actually unrelated.
Using toxicologic evidence, we may conjec-
ture that an agent has a potential to cause
human chronic disease, but we need further
evidence—in most cases epidemiologic evi-
dence—to establish a causal relationship
between the agent and a chronic disease in
humans. (I make a conceptual difference
between “establishing” and “proving,” the lat-
ter defined as “establishing truth,” which can
only be done for analytical statements.)
My statement that Goldstein criticizes was
misleading insofar as it seems to indicate that
we have to start from epidemiologic evidence
to ascribe an agent a hazardous potential for
human health. In many cases first informa-
tion on a potential hazard will stem from rou-
tine toxicologic testing. The last paragraphs of
my commentary (Kundi 2006) were intended
to give an outlook to future developments
that may provide answers to the question of
causation of chronic diseases in a more rapid
fashion. From this context it should be clear
that risk assessment was addressed with
respect to the causal role of an agent.
Therefore, a slight modification of the state-
ment above is appropriate: An agent cannot
be established to cause a chronic human dis-
ease unless supporting epidemiologic evidence
is available. Among other improvements,
comprehensive utilization of modern molecu-
lar biological methods integrated into epi-
demiologic designs may provide such
evidence at an early stage of the disease. 
The author declares he has no competing finan-
cial interests.
Michael Kundi
Institute of Environmental Health
Center for Public Health
Medical University of Vienna
Vienna, Austria
E-mail: Michael.Kundi@meduniwien.ac.at
REFERENCE
Kundi M. 2006. Causality and the interpretation of epidemiologic
evidence. Environ Health Perspect 114:969–974. 
Pitot HC, Dragan YP. 2001. Chemical carcinogenesis. In: Casarett and
Doull’s Toxicology: The Basic Science of Poisons (Klaassen CD,
ed). 6th ed. New York:McGraw-Hill, 241–319.
A 634 VOLUME 114 | NUMBER 11 | November 2006 • Environmental Health Perspectives
Correspondence